Os Therapies Inc. (OSTX)
AMEX AMEX Primary 
Small-Cap OS Therapies Inks Commercial Manufacture Agreements For Lead Cancer Drug For Rare Type Of Bone Cancer
On Friday, OS Therapies, Inc. (NYSE-A: OSTX) entered into agreements for the commercial manufacture of OST-HER2.
OS Therapies: A Cheap Mid-Stage Biotech Carrying Listeria-Based Immunotherapy
OSTX's OST-HER2 immunotherapy is in a fully enrolled phase 2b trial for osteosarcoma, which had an updated readout in mid-January 2025. Financially, OSTX has $7.9 million in cash, with recent funding providing a runway until 2026, but remains poorly capitalized and reliant on near-term news. Strengths include a mid-stage product for an unmet need, but risks involve past failures of Listeria-based immunotherapies and uncertain funding prospects.
OSTX CEO: "We Have a Lot of Milestones Coming" in Tumor Research
Paul Romness, CEO of OS Therapies (OSTX), joins Nicole Petallides at the NYSE after the company recently completed a critical phase of its Osteosarcoma research. As OS Therapies readies to send its data to the FDA, Paul discusses the similarities of the disease between humans and dogs and looks ahead to researching other solid tumors.
OS Therapies reports positive preclinical data for ovarian cancer treatment
OS Therapies Inc (NYSE-A:OSTX) announced encouraging preclinical results for its first therapeutic candidate targeting ovarian cancer. Preclinical data derived from tests conducted on KB and IGROV-1 mouse models of ovarian cancer demonstrated strong antitumor activity, the company said in a statement.
OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models
Folate receptor alpha targeting drug conjugate & hexa silanol exatecan (FRA-H) payloads tested in animal models of ovarian cancer Strong efficacy for FRA-H in KB and IGROV-1 mouse models of ovarian cancer Strong safety profile for FRA-H with no loss of bodyweight as compared with control in animal models Success of tADC proof-of-concept study paves way for creating multiple potential therapeutic candidates for preclinical and clinical evaluation NEW YORK, NY / ACCESSWIRE / September 11, 2024 / OS Therapies (NYSE American:OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announced positive data in animal models of ovarian cancer for its first therapeutic candidate developed based upon its proprietary tunable Antibody Drug Conjugate (tADC) platform. The first therapeutic candidate leverages a folate receptor alpha targeting small molecule combined with hexa-exatecan payloads (OST-tADC-FRA-H) linked together with the Company's proprietary silicone linker technology, SiLinker™.
OS Therapies Reports Second Quarter 2024 Financial Results
Successful IPO that raised $6.4 million on July 31, 2024, without issuing any warrants, occurred after the end of the second quarter and is not reflected in reported financials Conversion of all reported outstanding preferred shares and debt into equity occurred as of the date of the IPO and is not reflected in the reported financials After IPO and preferred shares and debt conversion share issuances, there are 20.85 million common shares outstanding, with 1.86 million common shares available to be traded Underwriter lockups limit potential for deposit or trading of remaining 18.99 million common shares As of the date of the IPO, Company had no debt, cash runway for lead program OST-HER2 into mid-2025 ROCKVILLE, MD / ACCESSWIRE / August 15, 2024 / OS Therapies, Inc. (NYSE American:OSTX) ("OS Therapies" or "the Company"), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today reported financial results for the second quarter of 2024 ended June 30, 2024. As of the date of our successful initial public offering (IPO) that occurred on July 31, 2024 on the NYSE American stock exchange, the Company successfully converted all of its outstanding preferred shares and debt into equity, raising $6.4 million in gross proceeds that provides the Company with cash runway through mid-2025, and received the support from the vast majority of its shareholders who signed 6-month underwriter lockup agreements, crucially through the fourth quarter 2024 readout of the fully-enrolled human Phase 2b clinical trial in resected, recurrent osteosarcoma, allowing the IPO to occur without the issuance of any warrants.
OS Therapies Announces Osteosarcoma Scientific and Medical Advisory Board
ROCKVILLE, MD / ACCESSWIRE / August 6, 2024 / OS Therapies (NYSE American:OSTX) ("OS Therapies" or "the Company"), an Antibody Drug Conjugate (ADC) and Immunotherapy research and clinical-stage biopharmaceutical company, highlights its Scientific and Medical Advisory Board (SMAB), comprised of experts in osteosarcoma from six institutions in the United States. The following physicians have agreed to serve on the OS Therapies SMAB: • Nabil M.
